Nearly one-third (n = 271; 32.2%) of participants had severe immunodeficiency, with a median CD4 count of 324.3 (IQR = 158–499) cells/mm3 with 44.0% (n = 370) classified as WHO clinical stage I. Forty-three (5.1%) participants had baseline anaemia, with mean Hgb of all participants at 13.8 (SD ±2.4) g/dl. Here, CD4 is linked to anemia.